IXICO plc Phase II Alzheimer's disease contract award (2025Z)
20 Mayo 2021 - 01:00AM
UK Regulatory
TIDMIXI
RNS Number : 2025Z
IXICO plc
20 May 2021
IXICO plc
("IXICO" or the "Company")
Phase II Alzheimer's disease contract award worth >GBP1m
IXICO plc (AIM:IXI), the AI data analytics company delivering
insights in neuroscience, announces that it has been awarded an
expansion contract by a current biopharmaceutical client to support
the company's Phase II Alzheimer's disease clinical trial .
Alzheimer's disease is a progressive degenerative disease affecting
approximately 50 million people worldwide with devastating
physical, emotional and financial impact to patients and
families.
Conducted across 125 sites in 10 countries, the clinical trial
will investigate efficacy, safety and tolerability of an anti-Tau
antibody treatment for individuals with prodromal and mild
Alzheimer's disease. For the study, IXICO will provide advanced
neuroimaging solutions involving structural magnetic resonance
imaging (MRI), volumetric MRI (vMRI), diffusion MRI (dMRI) and
arterial spin labelling (ASL).
The study is worth in excess of GBP1m over five years.
Lammert Albers, Chief Commercial Officer of IXICO, commented: "
IXICO is delighted to be awarded the contract for this Alzheimer's
disease clinical trial. With no available therapies to address the
underlying disease pathology, Alzheimer's disease remains a
critical area of unmet medical need, and we are proud to support
sponsors in their tireless efforts to bring potential treatments
for this devastating disease."
For further information please contact:
IXICO plc +44 (0)20 3763 7498
Giulio Cerroni, Chief Executive Officer
Grant Nash, Chief Financial Officer
Cenkos Securities PLC (Nominated adviser
and sole broker) +44 (0)20 7397 8900
Giles Balleny / Max Gould (Corporate
Finance)
Michael F Johnson / Russell Kerr
(Sales
Walbrook PR Ltd +44 (0)20 7933 8780
Paul McManus / Lianne Cawthorne IXICO@walbrookpr.com
/
Alice Woodings
About IXICO
IXICO is dedicated to delivering insights in neuroscience. Our
purpose is to advance medicine and human health by turning data
into clinically meaningful information, providing valuable new
insights in neuroscience and our goal is to be a leading proponent
of artificial intelligence in medical image analysis. We will
achieve this by developing and deploying breakthrough data
analytics, at scale, through our remote access technology platform,
to improve the return on investment in drug development and reduce
risk and uncertainty in clinical trials for our pharmaceutical
clients.
More information is available on www.IXICO.com and follow us on Twitter @IXICOnews
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
CNTDKCBBABKDCPD
(END) Dow Jones Newswires
May 20, 2021 02:00 ET (06:00 GMT)
Ixico (LSE:IXI)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Ixico (LSE:IXI)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024